Mono- and combinational drug therapies for global viral pandemic preparedness

Aleksandr Ianevski; Rouan Yao; Ronja M Simonsen; Vegard Myhre; Erlend Ravlo; Gerda D Kaynova; Eva Zusinaite; Judith M White; Stephen J Polyak; Valentyn Oksenych; Marc P Windisch; Qiuwei Pan; Eglė Lastauskienė; Astra Vitkauskienė; Algimantas Matukevičius; Tanel Tenson; Magnar Bjørås; Denis E Kainov

doi:10.1016/j.isci.2022.104112

Mono- and combinational drug therapies for global viral pandemic preparedness

iScience. 2022 Mar 17;25(4):104112. doi: 10.1016/j.isci.2022.104112. eCollection 2022 Apr 15.

Authors

Aleksandr Ianevski¹, Rouan Yao¹, Ronja M Simonsen¹, Vegard Myhre¹, Erlend Ravlo¹, Gerda D Kaynova², Eva Zusinaite³, Judith M White⁴, Stephen J Polyak⁵, Valentyn Oksenych¹, Marc P Windisch⁶, Qiuwei Pan⁷, Eglė Lastauskienė⁸, Astra Vitkauskienė⁹, Algimantas Matukevičius⁹, Tanel Tenson³, Magnar Bjørås¹, Denis E Kainov^{1

3

10}

Affiliations

¹ Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
² Vilnius Ozo Gymnasium, Vilnius University, Vilnius 07171, Lithuania.
³ Institute of Technology, University of Tartu, 50411 Tartu, Estonia.
⁴ University of Virginia, Department of Cell Biology, Charlottesville, VA, USA.
⁵ Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁶ Applied Molecular Virology Laboratory, Institut Pasteur Korea, 463-400 Gyeonggi-do, Korea.
⁷ Department of Gastroenterology and Hepatology, Erasmus MC-University, Medical Center, Rotterdam, Netherlands.
⁸ Life Sciences Center, Vilnius University, 10257 Vilnius, Lithuania.
⁹ Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania.
¹⁰ Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.

Abstract

Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by reviewing conserved druggable virus-host interactions, mechanisms of action, immunomodulatory properties of available broad-spectrum antivirals (BSAs), routes of BSA delivery, and interactions of BSAs with other antivirals. Based on the review, we concluded that the range of indications of BSAs can be expanded, and new pan- and cross-viral mono- and combinational therapies can be developed. We have also developed a new scoring algorithm that can help identify the most promising few of the thousands of potential BSAs and BSA-containing drug cocktails (BCCs) to prioritize their development during the critical period between the identification of a new virus and the development of virus-specific vaccines, drugs, and therapeutic antibodies.

Keywords: Chemistry; Pharmaceutical preparation; Pharmaceutical science; Pharmacology.

Publication types

Review